AGA Releases Guidelines on Use of Fecal and Blood Tests for Monitoring Ulcerative Colitis
The American Gastroenterological Association (AGA) released today new evidence-based guidelines for the use of non-invasive testing methods to identify biomarkers, as a first-line strategy for the monitoring and management of ulcerative colitis (UC) in patients both in remission and with active disease.
The updated guidelines, released today in the journal Gastroenterology, details use cases for three different biomarkers that can be used by clinicians to get an accurate read on each patient’s disease activity of UC. Two biomarkers, fecal calprotectin and fecal lactoferrin, can be detected in stool samples and the third, serum C-reactive protein (CRP) can be detected in blood samples. [read more]